Recent

% | $
Quotes you view appear here for quick access.

Immune Pharmaceuticals, Inc. Message Board

  • alesto12 alesto12 Apr 27, 2007 4:55 PM Flag

    Sublicensing agreement with Myriad Azixa?

    Read this press statement, last Friday

    Substansial sublicensing agreement (Azixa), I think Myriad are bringing in another partner for the EU and Asia market,let see on Tuesday(1 May Myriads conference call).

    "Myriad's findings are another indication of the substantial clinical opportunity that Azixa represents," remarked Jack Talley, President and Chief Executive Officer. "Our agreement with Myriad provides for significant financial benefits for EpiCept, both in the form of milestone payments and sublicensing income as well as future royalties in the event Myriad's development of Azixa continues to progress successfully. In addition, the progress made by Myriad with Azixa also provides further validation of the potential of our earlier-stage oncology programs. Notably, we are continuing with our Phase I trial of EPC2407, a novel, small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas, which was discovered through the same Anti-cancer Screening Apoptosis Program (ASAP) responsible for Azixa. EPC2407 is currently dosing its third cohort of patients in an ongoing Phase I study."

    Azixa is part of EpiCept's MX90745 series of apoptosis inducers, which was licensed to Myriad as part of an exclusive, worldwide development and commercialization agreement. Under the terms of the agreement, Myriad is responsible for all clinical development and commercialization of compounds from this series. Myriad is currently conducting two Phase II clinical trials for Azixa, one in patients with primary brain cancer and the other in melanoma that has spread to the brain


    Source:http://news.morningstar.com/news/ViewNews.asp?article=/PR/20070420NYF019_univ.xml&pgid=qtqnPress1

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • mid march huh? how bout early may LOL!

      I love his confidence during the last webcast oncology cc!

      vik

    • vkstuditi!

      There is "120-day" meeting this month with EMEA, the outcome og this meeting will be presented at latest in the middle of March according to Jack Talley, listen to their latest webcast.

      "120days" is a very important milestone in the EMEA process if positive then the rest is a piece of cake.

      Lets see if Myriad presents interesting news tomorrow

    • I am still unsure of any news regarding ceplene this month, but I could very well be wrong. What I am sure of is stocks like immu climbed as it was a "potential" for immunotherapy and is at $300M market cap with half the "potential" this stock has. I hope that the street starts to price in the acceptance of ceplene quickly as this would make the market cap more attractive than the $100M it is now. Usually, the big boys find these stocks first, just feels good don't it?

      vik

      ps. surgery is tuff stuff....

    • Don't worry alot of us love this stock as much as you, this should be a great month for us.

    • EPCT is currently about 5-times undervalued.

    • I am confused alesto? Is this sublicensing agreement that MYGN has with an EU partner good for epct? How will that generate more money for epct. The way I saw it was that milestones are all gravy ( total of like 10M) and those will be paid as the trials are either started or completed. now having said that, that is more revenue than they have ever generated! BUT, the licencsing agreement originally in place said that they would recieve mid single digit percent RAMPING UP TO DOUBLE DIGIT PERCENT OF SALES OF AZIXA!! meaning, 5% would ramp up to 10% of sales of a $2B drug! now what are you talking about and how would this affect the deal already in place?

      thanks in advance...
      vik

      • 2 Replies to vkstudti
      • vkstudti!

        Interesting newspipe in May

        1. Myriads webcast on Tuesday.

        - Phase II milestone payments?
        - Substansial sublicense agreement ?

        2. EMEA update (120 days)

        3. Epicepts conference
        http://investor.epicept.com/events.cfm

        4. BP Phase III studie

        5. NP-1 Phase III studie

      • vkstudti!

        Read this statement made bu Jack Talley last week, I don't know the details regarding the agreement between Myriad and Epicept,but according to analysts in Sweden that has been in contact with the management are sayiing thatthere are negotiations between Epicept and Azixa and that a sublicense agreement will give Epicept a substansial amount of money.


        "Myriad's findings are another indication of the substantial clinical opportunity that Azixa represents," remarked Jack Talley, President and Chief Executive Officer. "Our agreement with Myriad provides for significant financial benefits for EpiCept, both in the form of milestone payments and sublicensing income as well as future royalties in the event Myriad's development of Azixa continues to progress successfully."

    • Is Myriad presenting a partner for the EU and Asia market for Azixa?

      Friday 20:th of April

      The findings presented by Myriad indicate the potential of Azixa to act as a vascular disrupting agent (VDA), in addition to its previously demonstrated apoptosis inducing capabilities. Vascular disruption of a tumor's endothelium, the inner layer of cells lining a blood vessel, leads to a loss of blood supply to the tumor and subsequent tumor cell death.

      Myriad reported that Azixa induced cell death in several primary types of a tumor's endothelium, including micro-vessel endothelial cells. Myriad also reported that in human ovarian cancer xenografts, a single dose of Azixa induced dramatic tumor blood vessel damage and tumor cell death within 24 hours.

      "Myriad's findings are another indication of the substantial clinical opportunity that Azixa represents," remarked Jack Talley, President and Chief Executive Officer. "Our agreement with Myriad provides for significant financial benefits for EpiCept, both in the form of milestone payments and sublicensing income as well as future royalties in the event Myriad's development of Azixa continues to progress successfully. In addition, the progress made by Myriad with Azixa also provides further validation of the potential of our earlier-stage oncology programs. Notably, we are continuing with our Phase I trial of EPC2407, a novel, small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas, which was discovered through the same Anti-cancer Screening Apoptosis Program (ASAP) responsible for Azixa. EPC2407 is currently dosing its third cohort of patients in an ongoing Phase I study."

      Azixa is part of EpiCept's MX90745 series of apoptosis inducers, which was licensed to Myriad as part of an exclusive, worldwide development and commercialization agreement. Under the terms of the agreement, Myriad is responsible for all clinical development and commercialization of compounds from this series. Myriad is currently conducting two Phase II clinical trials for Azixa, one in patients with primary brain cancer and the other in melanoma that has spread to the brain.


      Source:http://investor.epicept.com/releasedetail.cfm?ReleaseID=238791

 
IMNP
0.356+0.007(+1.98%)Aug 26 3:59 PMEDT